if any, in the rates of valvulopathy (as defined by the Food and Drug
Administration, or FDA) in patients treated with lorcaserin and in the
control group did not meet the ESMB's predetermined stopping criteria.
o Announced the initiation of a Phase 1 clinical trial of a second
generation oral niacin receptor agonist intended for the treatment of
atherosclerosis in partnership with Merck & Co., Inc.
o Entered into strategic agreements with Siegfried Ltd primarily related
to the manufacturing of lorcaserin for Arena's planned New Drug
Application submission to the FDA and for commercialization of
lorcaserin after regulatory marketing approval. The agreements include
the purchase of certain drug product manufacturing and packaging
facility assets, including fixtures, equipment, other personal property
and real estate assets, located in Zofingen, Switzerland.
o Reported positive Phase 1a clinical trial results of APD791, Arena's
oral, internally discovered drug candidate intended for the treatment of
arterial thrombosis, and initiated a Phase 1b clinical trial to further
evaluate this drug candidate.
o Announced that initial clinical trial results for APD668, an oral drug
candidate discovered by Arena and being investigated for the treatment
of type 2 diabetes in partnership with Ortho-McNeil Pharmaceutical,
Inc., suggest that the Glucose-Dependent Insulinotropic Receptor, or
GDIR, improves glucose control in patients with type 2 diabetes. Based
on the data from those studies, Ortho-McNeil put APD668 on hold and
advanced a potentially more potent Arena-discovered GDIR agonist into
Scheduled Earnings Call
Arena will host both a conference call and webcast to discuss the first
quarter 2008 financial results and to provide a corporat
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved